Reference	Specie	Exposure period	Route	Doses	Age at analyses	Neuroanatomical analyses
Sexually dimorphic populations						
59	Sprague-Dawley rat	GD15 to PND10	Oral (diet)	BPA: 60, 600 ou 3000 ppm NP: 60, 600 ou 3000 ppm E2: 0.5 ppm	11 weeks	Unaffected volume of the SDN-POA.
56	Sprague-Dawley rat	48 h from PND1	Subcutaneous (total of 4 injections)	BPA: 250 µg/ 0.05ml Genistein: 250 µg/ 0.05ml E2: 50 µg/ 0.05ml	PND19	Increased number of tyrosine hydroxylase-ir cells in the AVPV of genistein and BPA groups , but not in E2-treated males. Diminished percentage of cells co-expressing ERα and tyrosine hydroxylase (TH) in AVPV of genistein and BPA groups.
57	Sprague-Dawley rat		Subcutaneous (total of 4 injections)	BPA: 250 µg/ 0.05ml Genistein: 250 µg/ 0.05ml	PND85: castrated animals primed with E2 and P	Unaffected volume, increased cell number of the SDN-POA by both BPA and genistein. Genistein, but not BPA increased AVPV volume. No effect on GnRH activation.
53	Sprague-Dawley rat	GD6 to PND0 PND1 to PND21	Oral (gavage)	BPA: 2.5 or 25 µg/kg/d EE: 5 or 10 µg/kg/d	PND21	Increased volume of SDN-POA at BPA-2.5 and 25 and EE2 10.
54	Long-Evans rat	GD12 to PND10	Oral	BPA: 10, 100, 1000 ou 10 000 µg/kg/d *EB: n = 2, data not shown	PND65-68	Reduced volume of SDN-POA at all doses. Reduced number of calbidin-immunoreactive cells in SDN-POA at 10 and 1000. Reduced number of TH-ir cells in AVPV at 10 and 10000.
55	Sprague-Dawley rat	28 prior to mating until PND140	Oral (diet)	Genistein: 5 ppm, 100 ppm, or 500 ppm NP: 25 ppm, 200 ppm, or 750 ppm	PND140	Genistein and NP increased the volume of the calbindin-SDN in male rats.
58	Sprague-Dawley rat	GD15-PND10	Diet	MXC: 24 - 240 - 1200 ppm Genistein: 20 - 200 -1000 ppm DINP: 400 - 4000 - 20000 ppm	Adult (11 weeks of age)	Unchanged SDN-POA volume at all treatments.
Sex steroid receptors and neuropeptides						
102	Sprague-Dawley rat	GD6 to GD21	Oral (gavage)	BPA: 2.5 or 25 µg/kg/d EE: 5 or 10 µg/kg/d	PND1	*No effects of BPA or EE on *Esr1* or *Esr2* mRNAs levels in AVPV or MPOA. *Effects since 2.5 in Mediobasal hypothalamus and MeA-posterodorsal/cortical.
103	Long-Evans rat	PND0 to PND2	Subcutaneous	BPA:50 µg/kg/d or 50 mg/kg/d EB: 10 µg/kg/d	PND4 and PND10	Reduced *Esr2* mRNAs levels in the BNST, paraventricular and supraoptic nuceli. No effects in the MeA.
105	BALB/c mice	GD0 to GD19	Oral	BPA: 2, 20 ou 200 µg/kg	PND28	Prefrontal cortex: no effect on *Esr1* and *Esr2* expression, increased Esrrγ levels. Hypothalamus: Increased expression of *Esr1*, *Esr2* and *Esrrγ* at BPA 2 and 20. Inversed or abolished sex differences at BPA- 2and 20 for ER genes. Increased hypothalamic expression of DNA methyltransferase (Dnmt) 1 at BPA 2 et 20.
108	C57BL6J mice	PND23-PND31	Subcutaneous	BPA: 50 µg/kg/d EB: 10 µg/kg/d	PND90	No effect on ERα immunoreactivity in the MeA, BST, lateral septum (LS), ventromedial hypothalamus (VMH) or arcuate nucelus.
109	Sprague-Dawley rat	GD6-birth	Oral (gavage)	BPA: 0 - 2.5 -25 - 250 - 2500 - 25000 µg/kg/d EE: 0.05 - 0.5 µg/kg/d	PND1	RNA sequencing: gene expression changes mainly observed in the hypothalamus. qRT-PCR: BPA and EE-0.5 increased hypothalamic expression of oxytocin.
107	C57BL/6 mice	7-10 days before mating until PND1	Oral (diet)	BPA: 5 mg/kg diet	PND90 (F1 and F3)	*F1: reduced AVP-immunoreactivity in the LS and MePD in BPA group. No changes in BNST. No effects on ERα in BNST, AVPV, MePD and VMH . *F3: No effect on AVP in LS, BNST and MePD . No effect on ERα in AVPV, MePD, VMH and BNST.
106	C57BL/6 mice	GD11to GD 17 and PND2 to PND6	Oral	DES: 0.3 or 3 µg/kg/d	36 to 37 weeks	Increased number of ERα-immunoreactive cells in the VMH at DES-3.
104	CD(SD)IGS rat	GD15-PND10	Diet	Genistein: 1000 ppm MXC: 24 - 240 - 1200 ppm DINP: 4000 - 20000 ppm EE: 0.05 ppm	PND10	EE increased SRC-1 expression in the POA; no changes in the expression of ERα, ERβ, PR, SRC1, SRC2, calbindin or GnRH. MXC at 1200 ppm reduced PR expression. Genistein or DINP did not change mRNAs levels of ERα, ERβ, PR or SRC1.